For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- JCR: EPO Biosimilar Props Up Business
June 13, 2011
- Patent Office to Resume Discussions on Patent Extension for DDS Formulations
June 13, 2011
- Korosho Approves Kowa's Menstrual Pain Relieving Agents as Class 1 OTC Drug
June 13, 2011
- Lilly Transfers Evista to Takeda in 7 Asian Markets
June 13, 2011
- Promotion Office Discussing Establishment of “Drug Discovery Support Institute”
June 13, 2011
- Prof. Kadowaki to Collect Evidence under Intensified Therapy Using Incretin-related Drugs
June 13, 2011
- Kyowa Kirin, Ferring to Copromote Desmopressin ODT for Enuresis
June 13, 2011
- Korosho to Make Unapproved Drugs under Development Available for Use
June 13, 2011
- Nippon Shinyaku to Market 3 PH Treatments Mid-decade
June 13, 2011
- Rights to PD Treatment KW-6002 in North America Returned to Kyowa Kirin
June 13, 2011
- Ono, DSP to Codevelop CTS as Additional Indication for Limaprost
June 13, 2011
- Bendamustine to Be Marketed by Eisai in South Korea: SymBio
June 13, 2011
- BMS, Roche to Collaborate in PI/II Trials of Combination Treatment for Melanoma
June 13, 2011
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…